Related Experiment Video

Updated: Jul 1, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according

S Malak1, M Wolf, G A Millot

  • 1Service d'Hématologie et de Thérapie Cellulaire, AP-HP, Hôpital Saint-Antoine and UPMC Université Paris 06, Paris, France.

Scandinavian Journal of Immunology
|September 11, 2008
PubMed

Insights

Severe ADAMTS13 deficiency in HIV-associated thrombotic microangiopathy (TMA) correlates with fewer AIDS complications and better prognosis. These HIV-TMA cases show outcomes comparable to idiopathic TMA, unlike those with detectable ADAMTS13 activity.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Nephrology

Background:

  • Human immunodeficiency virus (HIV) infection is a recognized risk factor for thrombotic microangiopathy (TMA).
  • The enzyme ADAMTS13 is crucial for cleaving von Willebrand factor, and its deficiency is implicated in TMA pathogenesis.
  • Understanding the specific role of ADAMTS13 deficiency in HIV-associated TMA is essential for predicting clinical presentation and outcomes.

Purpose of the Study:

  • To investigate the association between severe ADAMTS13 deficiency and clinical features in HIV-associated TMA.
  • To compare the outcomes of HIV-associated TMA with severe ADAMTS13 deficiency to cases with detectable ADAMTS13 activity.
  • To compare HIV-associated TMA outcomes with idiopathic TMA, stratified by ADAMTS13 activity levels.

Main Methods:

  • A prospective, multicenter, case-control study involving 236 patients within the French Network on TMA.
  • Analysis of 29 patients with HIV-associated TMA, categorized into severe ADAMTS13 deficiency (<5%) and detectable ADAMTS13 activity (>=5%).
  • Comparison with 62 patients with idiopathic TMA, also stratified by ADAMTS13 deficiency status.

Main Results:

  • HIV-associated TMA patients with severe ADAMTS13 deficiency (<5%) exhibited significantly fewer AIDS-related complications (23.5% vs. 91.6%) and higher median CD4+ T cell counts compared to those with detectable ADAMTS13 activity (>=5%).
  • TMA-associated mortality was higher in HIV-TMA patients with detectable ADAMTS13 activity (50%) versus severe deficiency (11.7%).
  • In patients with severe ADAMTS13 deficiency, TMA-associated mortality was comparable between HIV-positive (11.7%) and idiopathic TMA groups (15.5%). Conversely, HIV-TMA patients with detectable ADAMTS13 activity had higher mortality than idiopathic cases (P=0.04).

Conclusions:

  • HIV-associated TMA with severe ADAMTS13 deficiency is characterized by fewer AIDS complications and a higher CD4+ T cell count.
  • The prognosis for HIV-associated TMA with severe ADAMTS13 deficiency is favorable and similar to idiopathic TMA.
  • ADAMTS13 activity is a critical determinant of clinical presentation and outcome in HIV-associated TMA.

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Peptide-based Identification of Functional Motifs and their Binding Partners14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...